GlassScriptPhysician profile
Timothy Huntting
NPI 1598243396
$5,930.02
in general payments reported to CMS, 2019-2025
19 companies · $2,505 in 2025
The $2,505 reported for 2025 was more than what 98% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $140 · 2021: $354 · 2022: $632 · 2023: $760 · 2024: $1,321 · 2025: $2,505.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,229 · Travel and Lodging: $1,164 · Entertainment: $192.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,228.96 |
| Travel and Lodging | $1,164.42 |
| Entertainment | $192.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $2,490.08 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $560.37 | 2022-2025 | Infuse, Miebo, Revive |
| Alcon Vision LLC | $549.30 | 2022-2025 | Hydrus Microstent, Tryptyr, Precision7 |
| Dompe US, INC. | $298.42 | 2021-2025 | Oxervate |
| Oyster Point Pharma, INC. | $223.50 | 2024-2025 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $211.19 | 2024-2025 | Syfovre |
| Sun Pharmaceutical Industries INC. | $201.96 | 2020-2025 | |
| Optos, INC. | $192.42 | 2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Tarsus Pharmaceuticals, INC. | $192.29 | 2024-2025 | Xdemvy |
| Coopervision INC. | $184.47 | 2021-2024 | Onefit Contact Lens, Synergeyes Contact Lens |
| Ocular Therapeutix, INC. | $151.01 | 2024 | Dextenza |
| Biotissue Holdings INC. | $148.87 | 2022-2025 | |
| Lkc Technologies, INC. | $131.95 | 2024 | |
| Horizon Therapeutics Plc | $114.12 | 2023 | Tepezza |
| Astellas Pharma US INC | $109.98 | 2024 | Izervay |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $101.63 | 2022 | |
| Harrow Eye, LLC | $31.69 | 2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $21.77 | 2025 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Huntting listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.